



Addex First Half 2007 Financial Results Next Wednesday

Conference call & webcast at 15:30 CEST on 25 July 2007

Geneva, Switzerland, 18 July 2007 Addex Pharmaceuticals Ltd. (SWX:ADXN) will discuss its first half 2007 financial results during a conference call for the media, analysts, investors and other interested parties on Wednesday 25 July 2007 at 15:30 CEST (9:30am EDT).

Addex discovers and develops allosteric modulators, a different kind of small molecule therapeutic agent. The company's lead product has shown efficacy in gastroesophageal reflux disease (GERD) and migraine. Separately, Addex is collaborating with Ortho-McNeil, a Johnson & Johnson company.

Title: Addex Pharmaceuticals First Half 2007 Financial Results Conference Call

Date: 25 July 2007
Time: 15.30 ~ 16.30 CEST (9:30 ~ 10:30am EDT)

Dial-in numbers: +41 91 610 56 00 (Europe)
+44 207 107 0611 (UK)
+1 866 291 4166 (USA)

The webcast and slides will be available at: www.addexpharma.com

About Us

Addex Pharmaceuticals Ltd. discovers and develops allosteric modulators, a different kind of small molecule therapeutic agent. Allosteric modulation may offer more sophisticated ways to normalize biological signaling perturbed by disease compared to classical orthosteric agonist or antagonist drugs. Allosteric, literally translated from its Greek roots, means: other site. Thus, allosteric modulators bind receptors at sites that are distinct from the binding sites of classical small molecule orthosteric agonist and antagonist drugs.

In May 2007, Addex completed an initial public offering on the SWX Swiss Exchange, raising CHF137 million (\$111 million / €83 million). The IPO was the largest biotech IPO in Europe in three years.

The most advanced drug candidate, ADX10059, a negative allosteric modulator (NAM) of metabotropic glutamate receptor 5 (mGluR5), recently demonstrated clinically and statistically significant efficacy in separate Phase IIa clinical trials in gastroesophageal reflux disease (GERD) patients and migraine headache patients. Another phase IIa clinical trial of ADX10059 in acute anxiety is scheduled to finish in the second half of 2007. Data from a U.S. Phase IIa trial of ADX10061, an inlicensed orthosteric dopamine D1 receptor antagonist, for smoking cessation are due in the second half of 2007.

The Addex discovery capability has been validated through the signing of a collaborative deal with Ortho-McNeil, a Johnson & Johnson company. The deal is limited to discovery and development of allosteric modulators of metabotropic glutamate receptor 2 (mGluR2).

Contact

Chris Maggos
Head of Investor Relations & Communications
Addex Pharmaceuticals
+41 22 884 15 11 Direct
chris.maggos@addexpharma.com

www.addexpharma.com

T +41 22 884 15 55, F +41 22 884 15 56